Clinical Tip No.2: Too Much Vancomycin
🛑 THE PROBLEM
Vancomycin is overused in empiric therapy.
Not every patient needs MRSA coverage, and vancomycin carries a significant risk of nephrotoxicity.
🧠Key point many clinicians miss:
The primary reason to include vancomycin empirically is to cover MRSA.
In Europe, we’re mostly concerned with hospital-acquired MRSA (HA-MRSA), not community-acquired MRSA (CA-MRSA).
In the US, CA-MRSA is much more prevalent. That’s why American literature, guidelines, and textbooks often recommend MRSA coverage even for some community-acquired infections, such as purulent cellulitis.
In Europe, MRSA coverage is usually not needed for community-acquired infections unless the patient has clear risk factors for HA-MRSA, such as:
• Recent hospitalization and/or invasive procedure (e.g. surgery, central line)
• Hemodialysis
• Known MRSA infection or colonization within the past 6–12 months
• Use of broad-spectrum antibiotics within the past 3 months
✅ WHAT TO DO
In Europe, for community-acquired infections, consider vancomycin only if both of the following apply:
The infection clinically suggests S. aureus (e.g. cellulitis, necrotizing pneumonia)
The patient has clear risk factors for HA-MRSA
Otherwise, vancomycin is likely not indicated.
🎥 For more practical tips and a deeper explanation, check out my YouTube video:
https://www.youtube.com/watch?v=h9oiIjxH-HE
In the next post, I’ll explain when to safely discontinue vancomycin.
👥 If you found this helpful, share it with colleagues: hospitalists, ED and ICU teams, internists...
Take care!